- Home
- CAAP vs ACAD Comparison
CAAP vs ACAD Comparison
Compare CAAP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- ACAD
- Stock Information
- Founded
- CAAP 1998
- ACAD 1993
- Country
- CAAP Luxembourg
- ACAD United States
- Employees
- CAAP N/A
- ACAD N/A
- Industry
- CAAP Aerospace
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- ACAD Health Care
- Exchange
- CAAP Nasdaq
- ACAD Nasdaq
- Market Cap
- CAAP 2.9B
- ACAD 2.8B
- IPO Year
- CAAP 2018
- ACAD 2004
- Fundamental
- Price
- CAAP $18.22
- ACAD $17.07
- Analyst Decision
- CAAP Strong Buy
- ACAD Buy
- Analyst Count
- CAAP 2
- ACAD 17
- Target Price
- CAAP $22.00
- ACAD $24.00
- AVG Volume (30 Days)
- CAAP 523.4K
- ACAD 1.6M
- Earning Date
- CAAP 03-19-2025
- ACAD 05-07-2025
- Dividend Yield
- CAAP N/A
- ACAD N/A
- EPS Growth
- CAAP 18.23
- ACAD N/A
- EPS
- CAAP 1.75
- ACAD 1.36
- Revenue
- CAAP $1,843,267,000.00
- ACAD $957,797,000.00
- Revenue This Year
- CAAP $5.57
- ACAD $13.07
- Revenue Next Year
- CAAP $13.98
- ACAD $9.97
- P/E Ratio
- CAAP $10.41
- ACAD $12.55
- Revenue Growth
- CAAP 31.66
- ACAD 31.85
- 52 Week Low
- CAAP $13.97
- ACAD $14.15
- 52 Week High
- CAAP $20.79
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- CAAP 47.17
- ACAD 41.84
- Support Level
- CAAP $17.39
- ACAD $16.86
- Resistance Level
- CAAP $19.39
- ACAD $17.31
- Average True Range (ATR)
- CAAP 0.82
- ACAD 0.51
- MACD
- CAAP 0.07
- ACAD 0.02
- Stochastic Oscillator
- CAAP 38.35
- ACAD 43.24
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.